$5.375
0.005[0.09%]
Last update: 9:36AM Get Real Time Here
Amneal Pharmaceuticals
(NASDAQ:AMRX)Amneal Pharmaceuticals Stock (NASDAQ:AMRX), Analyst Ratings, Price Targets, Predictions
Amneal Pharmaceuticals Inc has a consensus price target of $6.65, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Goldman Sachs, and Barclays on March 21, 2024, March 4, 2024, and January 29, 2024. With an average price target of $7.42 between Piper Sandler, Goldman Sachs, and Barclays, there's an implied 37.98% upside for Amneal Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Goldman Sachs
Barclays
Truist Securities
BMO Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Amneal Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/21/2024 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | 48.84% | Piper Sandler | David Amsellem | $6 → $8 | Maintains | Overweight | Get Alert |
| 03/04/2024 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | 16.28% | Goldman Sachs | Nathan Rich | $5.5 → $6.25 | Maintains | Buy | Get Alert |
| 01/29/2024 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | 48.84% | Barclays | Balaji Prasad | $6 → $8 | Maintains | Overweight | Get Alert |
| 11/08/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | 30.23% | Truist Securities | Gregory Fraser | $6 → $7 | Maintains | Buy | Get Alert |
| 09/06/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | 11.63% | Truist Securities | Gregory Fraser | → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | -6.98% | Piper Sandler | David Amsellem | $3 → $5 | Maintains | Overweight | Get Alert |
| 08/07/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | 11.63% | Truist Securities | Gregory Fraser | $4 → $6 | Maintains | Buy | Get Alert |
| 08/07/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | -6.98% | Barclays | Balaji Prasad | $4 → $5 | Maintains | Overweight | Get Alert |
| 05/08/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | -44.19% | Piper Sandler | David Amsellem | $5 → $3 | Maintains | Overweight | Get Alert |
| 03/29/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | -25.58% | Truist Securities | Gregory Fraser | $5 → $4 | Maintains | Buy | Get Alert |
| 03/10/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | -25.58% | Barclays | Balaji Prasad | $7 → $4 | Maintains | Overweight | Get Alert |
| 03/03/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | -44.19% | Goldman Sachs | Nathan Rich | $3.5 → $3 | Maintains | Buy | Get Alert |
| 03/03/2023 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | -25.58% | BMO Capital | Gary Nachman | $5 → $4 | Maintains | Market Perform | Get Alert |
| 08/08/2022 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | -25.58% | Goldman Sachs | Nathan Rich | $4.5 → $4 | Maintains | Buy | Get Alert |
| 05/12/2022 | AMRX | Buy Now | Amneal Pharmaceuticals | $5.38 | -16.28% | Goldman Sachs | Nathan Rich | $6 → $4.5 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Amneal Pharmaceuticals (AMRX)?
The latest price target for Amneal Pharmaceuticals (NASDAQ: AMRX) was reported by Piper Sandler on March 21, 2024. The analyst firm set a price target for $8.00 expecting AMRX to rise to within 12 months (a possible 48.84% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amneal Pharmaceuticals (AMRX)?
The latest analyst rating for Amneal Pharmaceuticals (NASDAQ: AMRX) was provided by Piper Sandler, and Amneal Pharmaceuticals maintained their overweight rating.
When was the last upgrade for Amneal Pharmaceuticals (AMRX)?
There is no last upgrade for Amneal Pharmaceuticals.
When was the last downgrade for Amneal Pharmaceuticals (AMRX)?
There is no last downgrade for Amneal Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Amneal Pharmaceuticals (AMRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amneal Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amneal Pharmaceuticals was filed on March 21, 2024 so you should expect the next rating to be made available sometime around March 21, 2025.
Is the Analyst Rating Amneal Pharmaceuticals (AMRX) correct?
While ratings are subjective and will change, the latest Amneal Pharmaceuticals (AMRX) rating was a maintained with a price target of $6.00 to $8.00. The current price Amneal Pharmaceuticals (AMRX) is trading at is $5.38, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.